Paclitaxel (PTX)-loaded solid lipid nanoparticles without hydroxyl-β-cyclodextrin (PS) or with hydroxypropyl-β-cyclodextrin (PSC) were prepared by hot-melted sonication. Biocompatible and biodegradable stearic acid was used to produce the solid matrix. The stability of PS and PSC was assessed at different temperatures. Drug stability, as assessed by encapsulation efficiency (EE; %), particle size, and the polydispersity index (PDI), was examined and in vitro release of PTX from PS or PSC for up to 180 days was assessed. After 180 days of storage at 25 °C, no significant change in particle size, PDI, or EE of PS or PSC was observed. PS and PSC displayed similar sustained PTX release patterns. The particle size, PDI, EE, PTX release profile, and cytotoxicity of PS changed significantly with increasing incubation time, whereas those of PSC showed no significant change, when samples were stored at 40 ± 2 °C. PSC was more stable than PS in plasma with regard to particle size and PDI. These results demonstrate that PSC could be a promising formulation to increase drug stability.
Keywords: Hydroxypropyl-β-cyclodextrin; Paclitaxel; Solid lipid nanoparticle; Stability.